Cargando…
The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
International schizophrenia guidelines endorse seeking the patient's preference for guiding antipsychotic therapy. There exists a small niche of patients who prefer, or are required to use, long-acting injectable antipsychotic medications due to the adherence benefit. However, they may not be a...
Autores principales: | Evernden, Christopher, Giang, Irene, Anderson, Mariah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
College of Psychiatric & Neurologic Pharmacists
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463006/ https://www.ncbi.nlm.nih.gov/pubmed/34621608 http://dx.doi.org/10.9740/mhc.2021.09.305 |
Ejemplares similares
-
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such, Pedro, et al.
Publicado: (2021) -
Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
por: Mason, Katy, et al.
Publicado: (2021) -
Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
por: Brown, Brianne, et al.
Publicado: (2019) -
Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Patel, R., et al.
Publicado: (2018) -
S200. COMPARISON BETWEEN LONG-ACTING INJECTABLE ARIPIPRAZOLE VERSUS PALIPERIDONE PALMITATE IN THE TREATMENT OF SCHIZOPHRENIA: SYSTEMATIC REVIEW AND INDIRECT TREATMENT COMPARISON
Publicado: (2020)